| Literature DB >> 31200358 |
Andrew D Zelenetz1, Leo I Gordon2, Jeremy S Abramson3, Ranjana H Advani4, Nancy L Bartlett5, Paolo F Caimi6, Julie E Chang7, Julio C Chavez8, Beth Christian9, Luis E Fayad10, Martha J Glenn11, Thomas M Habermann12, Nancy Lee Harris3, Francisco Hernandez-Ilizaliturri13, Mark S Kaminski14, Christopher R Kelsey15, Nadia Khan16, Susan Krivacic17, Ann S LaCasce18, Amitkumar Mehta19, Auayporn Nademanee20, Rachel Rabinovitch21, Nishitha Reddy22, Erin Reid23, Kenneth B Roberts24, Stephen D Smith25, Erin D Snyder19, Lode J Swinnen26, Julie M Vose27, Mary A Dwyer28, Hema Sundar28.
Abstract
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31200358 DOI： 10.6004/jnccn.2019.0029
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908